Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma

NCT07492914 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Resectable Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Sacituzumab Govitecan
DRUG: Tagitanlimab

Sponsor

West China Hospital